EDITORIAL

1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

ORIGINALARTICLE

1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
2. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
3. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma:a prospective phase II trial
4. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
5. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
6. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
7. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
8. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
9. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria:a follow-up of at least 5 years

ERRATUM

1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

REVIEW

1. Eliciting pyroptosis to fuel cancer immunotherapy:mechanisms and strategies
2. Living biobank-based cancer organoids: prospects and challenges in cancer research